ICER Case Study: Migraine
April 25, 2018
Migraine is one of the most prevalent neurological disorders worldwide, associated with substantial health, sociological, and economic consequences. The current treatment options for migraine are medicines that were developed for other diseases, such as hypertension, depression, and epilepsy.
During the last decade, however, new medicines have been developed to explicitly target the causes of migraine. They are known as CGRP inhibitors, because they block the small protein calcitonin gene-related peptide, preventing the onset of a migraine headache.
Evaluating the benefits of CGRP inhibitors will culminate in ICER’s estimated value-based price. This price will, by necessity, assume that these medicines’ value to each individual patient can be evaluated based on the medicine’s average value to the entire migraine population.
That is not the reality.
Tags: Cost Value, Headache, Neurological
Categorized in: Analysis